The estimated Net Worth of William Ho is at least $3.35 Миллион dollars as of 21 December 2023. Dr Ho owns over 2,500 units of RAPT Therapeutics stock worth over $28,989 and over the last 5 years he sold RAPT stock worth over $2,794,020. In addition, he makes $530,000 as Chief Medical Officer at RAPT Therapeutics.
Dr has made over 71 trades of the RAPT Therapeutics stock since 2020, according to the Form 4 filled with the SEC. Most recently he sold 2,500 units of RAPT stock worth $54,200 on 21 December 2023.
The largest trade he's ever made was exercising 8,356 units of RAPT Therapeutics stock on 16 November 2020 worth over $52,225. On average, Dr trades about 1,973 units every 17 days since 2019. As of 21 December 2023 he still owns at least 15,020 units of RAPT Therapeutics stock.
You can see the complete history of Dr Ho stock trades at the bottom of the page.
Dr. William Ho is the Chief Medical Officer at RAPT Therapeutics.
As the Chief Medical Officer of RAPT Therapeutics, the total compensation of Dr Ho at RAPT Therapeutics is $530,000. There are 4 executives at RAPT Therapeutics getting paid more, with Rodney Young having the highest compensation of $2,296,220.
Dr Ho is 55, he's been the Chief Medical Officer of RAPT Therapeutics since . There are 8 older and 6 younger executives at RAPT Therapeutics. The oldest executive at RAPT Therapeutics, Inc. is Mary Gray, 67, who is the Independent Director.
William's mailing address filed with the SEC is C/O RAPT THERAPEUTICS, INC., 561 ECCLES AVENUE, SOUTH SAN FRANCISCO, CA, 94080.
Over the last 5 years, insiders at RAPT Therapeutics have traded over $79,325,123 worth of RAPT Therapeutics stock and bought 4,298,405 units worth $48,553,258 . The most active insiders traders include Peter Svennilson, David V Goeddel и Fund L.P.Topspin Biotech Fu.... On average, RAPT Therapeutics executives and independent directors trade stock every 11 days with the average trade being worth of $127,774. The most recent stock trade was executed by Dirk G. Brockstedt on 5 January 2024, trading 898 units of RAPT stock currently worth $20,456.
RAPT Therapeutics, Inc., a clinical-stage immunology-based biopharmaceutical company, focuses on discovering, developing, and commercializing oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases. Its lead oncology drug candidate is FLX475, an oral small molecule C-C motif chemokine receptor 4 antagonist that is in the Phase 1/2 clinical trial to investigate as a monotherapy and in combination with pembrolizumab in patients with advanced cancer. The company's lead inflammation drug candidate is RPT193 to selectively inhibit the migration of type 2 T helper cells into inflamed tissues. It is also pursuing a range of targets, including general control nonderepressible 2 and hematopoietic progenitor kinase 1 that are in the discovery stage of development. The company was formerly known as FLX Bio, Inc. and changed its name to RAPT Therapeutics, Inc. in May 2019. RAPT Therapeutics, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.
RAPT Therapeutics executives and other stock owners filed with the SEC include: